3645 results for «586»
3645 results
TAVI in heart failure is possible
21 May 2026 – From EuroPCR 2026
This session demonstrates the feasibility of transcatheter aortic valve implantation (TAVI) in patients with heart failure through a series of challenging cases. It covers sequential management of hypertrophic obstructive cardiomyopathy with aortic stenosis, advanced heart failure interventions, staged approaches in cardiogenic shock, and complex percutaneous interventions...
Refining the gold standard: what is new in DES
21 May 2026 – From EuroPCR 2026
This session explores recent advancements in drug-eluting stent (DES) technology, featuring global real-world evidence on short dual antiplatelet therapy (DAPT) with polymer-free DES, angiographic outcomes from pooled TARGET trials, and real-world registry data on various DES platforms. It also presents post-marketing surveillance results and systematic reviews...
Calcified lesion of distal protected left main - LIVE case
22 May 2026 – From EuroPCR 2026
An 85‑year‑old man with type 2 diabetes mellitus, hypertension, dyslipidemia, peripheral artery disease, COPD, and chronic kidney disease presented with CCS class II angina related to three‑vessel coronary artery disease. He had previously undergone hybrid revascularization, including PCI of the RCA ostium and CABG with LIMA...
Diagnosis and management of INOCA and ANOCA
21 May 2026 – From EuroPCR 2026
This session focuses on the diagnosis and management of ischemia and angina with non-obstructive coronary arteries (INOCA and ANOCA). It presents safety data from coronary function testing, patient outcomes after comprehensive ischemia assessment, and endotype-specific treatment effects. Further topics include coronary sinus reducer therapy, the impact...
Insights from the Corevalve US Pivotal and SURTAVI trials
05 Apr 2022
Pierre Deharo and Giuseppe Di Gioia provide their take on this analysis of the 5 years incidence, outcomes and predictors of hemodynamic SVD in patients undergoing TAVI and surgery from the Corevalve US Pivotal and SURTAVI trials.
Author
Author
